Beijing Luzhu Biotechnology Co., Ltd.
2480.HK·HKSE·Healthcare
15.4000.000 (0.00%)today
At close: Nov 5, 3:24 PM HKT · May be delayed up to 15 min · HKD
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close15.400
Open15.400
Day range—
52-week range12.00025.960
Off day high0.00%
Off 52-week high−40.68%
Volume200
Avg. volume (3M)590
Market cap3.06B
EPS (TTM)-0.7500
Forward P/E12.72
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)-0.65
Shares outstanding198.91M
Short interest—
Earnings date—
Analyst target31.714
Profit margin0.00%
Against its peers
Compare in full ›| 2480.HK | 688520.SS | 8SJ.F | VIR | 2509.HK | 688177.SS | |
|---|---|---|---|---|---|---|
| Market cap | 3.06B | 15.35B | 1.84B | 1.95B | 3.31B | 7.38B |
| P/E (TTM) | — | — | — | — | 5.4 | — |
| Forward P/E | 12.7 | 21.9 | — | -4.7 | 18.3 | -26.2 |
| Price/book | 4.4 | -22.6 | 2.4 | 2.1 | 3.3 | 171.3 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −32.40% | −37.00% | −37.59% | +129.88% | −36.17% | −34.43% |
| Today | 0.00% | +1.02% | +1.70% | −2.12% | −0.40% | +2.95% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 2480.HK news ›Beijing Luzhu Biotechnology Says Recombinant RSV Vaccine Approved For Clinical Trials In China
TradingView Beijing Luzhu Biotechnology Says Recombinant RSV Vaccine Approved For Clinical Trials In China
From the 4Search news index, newest first.